ArticleAmerican health & drug benefits2018
Patient Preferences and Therapeutic Satisfaction with Topical Agents for Rosacea: A Survey-Based Study.
Article in American health & drug benefits, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.
- Health-related Quality of Life of Patients with Rosacea: A Systematic Review and Meta-analysis of Real-world Data.Acta dermato-venereologica · 2024Pooled it
- The exposomal imprint on rosacea: More than skin deep.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Review
- Prescriber Phenotypes: Variability in Topical Rosacea Treatment Patterns Among United States Dermatologists.Journal of clinical medicine · 2024Article
- Real-World Adverse Events Associated with Encapsulated Benzoyl Peroxide/Tretinoin, 3%/0.1%, and Encapsulated Benzoyl Peroxide, 5.Dermatology and therapy · 2024Article
- Long-term Efficacy and Safety of Microencapsulated Benzoyl Peroxide Cream, 5%, in Rosacea: Results From an Extension of Two Phase III, Vehicle-controlled Trials.The Journal of clinical and aesthetic dermatology · 2023Article
- Efficacy and Safety of Microencapsulated Benzoyl Peroxide Cream, 5%, in Rosacea: Results From Two Phase III, Randomized, Vehicle-Controlled Trials.The Journal of clinical and aesthetic dermatology · 2023Article
- Impact of Topical Vehicles and Cutaneous Delivery Technologies on Patient Adherence and Treatment Outcomes in Acne and Rosacea.The Journal of clinical and aesthetic dermatology · 2023Review
- Patient-Centric Design of Topical Dermatological Medicines.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Enhancing Topical Pharmacotherapy for Acne and Rosacea: Vehicle Choices and Outcomes.The Journal of clinical and aesthetic dermatology · 2022Review
- The Importance of Assessing Burning and Stinging when Managing Rosacea: A Review.Acta dermato-venereologica · 2021Review
- Reliability and Validity of the Treatment Satisfaction with Medicines Questionnaire (SATMED-Q) in Persons with Arterial Hypertension.International journal of environmental research and public health · 2021Article
- Willingness-to-Pay and Benefit-Cost Analysis of Botulinum Toxin for the Treatment of Rosacea in China: Findings from a Web-Based Survey.Patient preference and adherence · 2021Article
- Patient Preferences and Therapeutic Satisfaction with Topical Agents for Rosacea: A Survey-Based Study.American health & drug benefits · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRosacea is a chronic inflammatory skin disorder that primarily affects the convexities of the central face. Depending on the severity and type of rosacea, physicians may prescribe interventions such as behavioral changes, laser and intense pulsed light, as well as various pharmacologic therapies, including topical agents. The impact of side effects associated with topical treatments for rosacea on patient preferences and treatment satisfaction is not well-documented.
objectiveTo assess patients' concerns, treatment satisfaction, and quality of life (QOL) associated with topical treatments for rosacea.
methodsPatients were identified for participation in a one-time survey from electronic medical records between 2010 and 2015 from the largest privately held and physician-run multispecialty group practice in Massachusetts. Patients were eligible to participate in the survey if they were aged ≥18 years and had ≥1 diagnoses of rosacea, ≥1 prescriptions for topical metronidazole gel/cream or azelaic acid gel, ≥6 months of follow-up, and an active treatment record in 2014. Treatment-related concerns and their importance were assessed using a questionnaire developed for this study. Treatment satisfaction and QOL were evaluated using the Treatment Satisfaction with Medicines Questionnaire (SATMED-Q) and the Dermatology Life Quality Index (DLQI), respectively.
resultsOf the 900 eligible patients surveyed, 216 (24%) responded. Among the responders, 122 reported currently using a topical rosacea treatment. The most common treatment-related concerns were efficacy (64.8%), skin dryness (18.4%), unspecified side effects (9.6%), burning sensation (8.8%), and application technique (8.0%). The treatment-related concerns that were assessed as most important by responders included efficacy (mean score 9.1, on a 10-point scale), soreness (7.6), itching (7.5), burning (7.4), and dryness (7.3). Averaged across all the responders, treatment satisfaction was rated as neutral (mean SATMED-Q score, 56.5), whereas the impact of rosacea on QOL was minimal (mean DLQI score, 2.7). Increasing dryness was significantly associated with worsening QOL, and trends toward significance were observed for increasing soreness, itching, and burning sensations.
conclusionsThe survey results suggest a need for novel topical therapies for patients with rosacea that have increased efficacy and tolerability, which may improve patient satisfaction and QOL.
Indexed as
Identifiers
29915642PMC5973247W3024109368What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.